Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2021

13.06.2021 | Commentary

Logistics management provides greater efficiency, governance and compliance

verfasst von: Francesco Ferrara, Priscilla Santilli, Antonio Vitiello, Giampiero Forte, Vilma D’Aiuto

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

During the 2020 Congress of the Italian Society of Hospital Pharmacy (Sifo 2020), there was a heated debate about whether it is more convenient to dispense healthcare directly in hospitals and public facilities, or indirectly, through the use of external private pharmacies. The former solution is called “direct dispensing” (DD), while the latter is called “dispensing on commission” (DPC). The strengths and advantages of DD over DPC are many: greater therapeutic appropriateness due to direct control of treatment plans, cost savings from external commissions, and greater clinical sharing of treatment by all healthcare personnel. The main weakness is the organization of a complex warehouse. As the number of chronic patients and advanced therapies increases, direct care requires a new structure and logistics system to manage large administrative, accounting, and information flows. The purpose of this article is to compare the two logistic models implemented in Italy in order to structure a computerized model that can increase the efficiency of the National Health System (NHS).
Literatur
2.
Zurück zum Zitat Ciacca A. Malattie Croniche: riorganizzazione dei percorsi di cura e dell’assistenza farmaceutica territoriale. Boll SIFO 2020;66(6):346–354. Ciacca A. Malattie Croniche: riorganizzazione dei percorsi di cura e dell’assistenza farmaceutica territoriale. Boll SIFO 2020;66(6):346–354.
4.
Zurück zum Zitat Ferrara F, Santilli P, Bartolini L, Vitiello A, Pennacchia A, Di Croce S, et al. L’importanza del magazzino logistico in periodo di pandemia: l’esperienza dell’USL Umbria 1 durante covid-19. Recenti Prog Med. 2021;112(3):219–24.PubMed Ferrara F, Santilli P, Bartolini L, Vitiello A, Pennacchia A, Di Croce S, et al. L’importanza del magazzino logistico in periodo di pandemia: l’esperienza dell’USL Umbria 1 durante covid-19. Recenti Prog Med. 2021;112(3):219–24.PubMed
5.
Zurück zum Zitat Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia? Ital J Med. 2020;14(2):88–94. Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia? Ital J Med. 2020;14(2):88–94.
6.
Zurück zum Zitat Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;1–4. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;1–4.
7.
Zurück zum Zitat Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul;27:bmjebm–2020. Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul;27:bmjebm–2020.
8.
Zurück zum Zitat Ferrara F, Porta R, Santilli P, D’Aiuto V, Vitiello A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020;52(5):441–2.CrossRef Ferrara F, Porta R, Santilli P, D’Aiuto V, Vitiello A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020;52(5):441–2.CrossRef
9.
Zurück zum Zitat Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;S1359-6446(21)00037 – 4. Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;S1359-6446(21)00037 – 4.
10.
Zurück zum Zitat Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021;147:110486.CrossRef Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021;147:110486.CrossRef
11.
Zurück zum Zitat Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021;1–5. Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021;1–5.
12.
Zurück zum Zitat Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020;1–2. Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020;1–2.
13.
Zurück zum Zitat Vitiello A, Ferrara F, Porta R. Remdesivir. and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;1–2. Vitiello A, Ferrara F, Porta R. Remdesivir. and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;1–2.
14.
Zurück zum Zitat Ferrara F, Porta R, D’Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;1–2. Ferrara F, Porta R, D’Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;1–2.
15.
Zurück zum Zitat Vitiello A, La Porta R, D’Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;S0198-8859(21)00014 – 8. Vitiello A, La Porta R, D’Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;S0198-8859(21)00014 – 8.
16.
Zurück zum Zitat Ferrara F, Vitiello A. Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. 2020;15:1.CrossRef Ferrara F, Vitiello A. Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. 2020;15:1.CrossRef
17.
Zurück zum Zitat Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;262:118510.CrossRef Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;262:118510.CrossRef
18.
Zurück zum Zitat Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021;156:105579.CrossRef Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021;156:105579.CrossRef
19.
Zurück zum Zitat Vitiello A, La Porta R, Ferrara F. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020;bmjebm-2020-111589. Vitiello A, La Porta R, Ferrara F. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020;bmjebm-2020-111589.
20.
Zurück zum Zitat Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114–5. Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114–5.
Metadaten
Titel
Logistics management provides greater efficiency, governance and compliance
verfasst von
Francesco Ferrara
Priscilla Santilli
Antonio Vitiello
Giampiero Forte
Vilma D’Aiuto
Publikationsdatum
13.06.2021
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-021-01283-6

Weitere Artikel der Ausgabe 5/2021

International Journal of Clinical Pharmacy 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.